Characteristics | Placebo (n = 27) | Rosuvastatin (n = 36) | p value | ||
---|---|---|---|---|---|
Baseline | Followup | Baseline | Followup | ||
Age, y | 56 ± 12 | 59 ± 14 | 0.38 | ||
Hemodynamics | |||||
HR (bpm) | 68 ± 8 | 69 ± 12 | 72 ± 9 | 71 ± 10 | 0.54 |
SBP (mm Hg) | 130 ± 17 | 128 ± 11 | 130 ± 14 | 130 ± 15 | 0.81 |
DBP (mm Hg) | 77 ± 11 | 74 ± 11 | 77 ± 11 | 75 ± 9 | 0.41 |
Aortic Valve Parameters | |||||
AVA (cm2) | 1.5 ± 0.5 | 1.1 ± 0.3* | 1.5 ± 0.4 | 1.1 ± 0.4† | 0.58 |
AV peak velocity (m/s) | 3.2 ± 0.1 | 3.9 ± 0.7* | 3.2 ± 0.1 | 3.8 ± 0.5† | 0.64 |
AV peak gradient (mm Hg) | 41 ± 4 | 62 ± 23* | 42 ± 4 | 59 ± 14† | 0.35 |
AV mean gradient (mm Hg) | 22 ± 4 | 35 ± 13* | 23 ± 3 | 34 ± 9† | 0.63 |
Left Heart Dimensions | |||||
IVS (mm) | 11 ± 2 | 11 ± 2 | 11 ± 2 | 11 ± 2 | 0.95 |
PWT (mm) | 10 ± 1 | 11 ± 2 | 11 ± 1 | 11 ± 2 | 0.56 |
LA (mm) | 36 ± 6 | 37 ± 7 | 39 ± 7 | 39 ± 7 | 0.42 |
LVEDD (mm) | 48 ± 6 | 47 ± 5 | 48 ± 6 | 47 ± 6 | 0.92 |
LVESD (mm) | 29 ± 5 | 27 ± 5 | 28 ± 5 | 27 ± 6 | 0.36 |
LV mass/BSA (g/m2) | |||||
Men | 93 ± 22 | 94 ± 20 | 93 ± 24 | 96 ± 17 | 0.51 |
Women | 82 ± 17 | 84 ± 19 | 81 ± 14 | 83 ± 19 | 0.72 |
EF (%) | 66 ± 5 | 66 ± 6 | 68 ± 6 | 68 ± 7 | 0.89 |
Conventional Diastolic Parameters | |||||
Mitral E velocity (cm/sec) | 80 ± 15 | 81 ± 22 | 81 ± 22 | 80 ± 27 | 0.64 |
Mitral A velocity (cm/sec) | 80 ± 27 | 78 ± 22 | 80 ± 27 | 79 ± 28 | 0.82 |
E/A ratio | 1.0 ± 0.3 | 1.1 ± 0.2 | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.65 |
Tissue Doppler Imaging | |||||
Lateral S' | 8.1 ± 1.9 | 8.1 ± 1.6 | 8.2 ± 1.8 | 8.3 ± 2.2 | 0.72 |
Lateral E' | 7.0 ± 1.2 | 6.0 ± 2.1* | 7.1 ± 3.2 | 6.1 ± 2.6† | 0.66 |
Lateral A' | 10.1 ± 3.1 | 9.4 ± 3.5 | 10.6 ± 3.6 | 10.3 ± 2.3 | 0.55 |
E/E' (lateral) | 11 ± 4 | 15 ± 3* | 11 ± 3 | 15 ± 4† | 0.62 |